Kimmtrak (tebentafusp-tebn) / Medison, Immunocore  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kimmtrak (tebentafusp-tebn) / Immunocore
NCT02889861 / 2016-002236-32: IMCgp100-401 Rollover Study

Terminated
2
3
Europe, US
IMCgp100
Immunocore Ltd
Malignant Melanoma
04/19
04/19
IMCgp100-202, NCT03070392 / 2015-003153-18: Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Active, not recruiting
2
378
Europe, Canada, US, RoW
IMCgp100, Dacarbazine, DTIC-Dome, DTIC, DIC, Imidazole Carboxamide, Ipilimumab, Yervoy, Pembrolizumab, Keytruda
Immunocore Ltd
Uveal Melanoma
10/20
06/25
NCT06414590: Neoadjuvant Tebentafusp for Uveal Melanoma

Not yet recruiting
2
19
US
Tebentafusp-Tebn
Thomas Jefferson University
Locally Advanced Unresectable Uveal Melanoma
04/25
10/28
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
NCT06070012: Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Not yet recruiting
2
44
US
Tebentafusp, Kimmtrak
Diwakar Davar, Immunocore Ltd
Uveal Melanoma
06/26
06/29
IMCgp100-102, NCT02570308 / 2015-004222-34: A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Completed
1/2
146
Europe, Canada, US
IMCgp100, Tebentafusp, Kimmtrak
Immunocore Ltd
Uveal Melanoma
03/20
10/22
NCT02535078 / 2015-002971-12: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Checkmark OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Jun 2022 - Jun 2022: OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Completed
1/2
113
US
Tebentafusp (IMCgp100), durvalumab, MEDI4736, tremelimumab
Immunocore Ltd, AstraZeneca
Malignant Melanoma
06/23
06/23
IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Recruiting
1/2
727
Europe, Canada, US, RoW
IMC-F106C, IMC-F106C and pembrolizumab, IMC-F106C and chemotherapy, IMC-F106C and monoclonal antibodies and chemotherapy, IMC-F106C and tebentafusp, IMC-F106C and bevacizumab, IMC-F106C and kinase inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
06/26
06/26

Download Options